Reply to Jorge Esteban-Villarrubia and Guillermo De Velasco's Letter to the Editor re: Daniel S. Roberson, Vidit Sharma, Stephen A. Boorjian, et al. Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis. Eur Urol 2025;88:212-4.
APA
Roberson DS, Khanna A (2025). Reply to Jorge Esteban-Villarrubia and Guillermo De Velasco's Letter to the Editor re: Daniel S. Roberson, Vidit Sharma, Stephen A. Boorjian, et al. Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis. Eur Urol 2025;88:212-4.. European urology. https://doi.org/10.1016/j.eururo.2025.11.017
MLA
Roberson DS, et al.. "Reply to Jorge Esteban-Villarrubia and Guillermo De Velasco's Letter to the Editor re: Daniel S. Roberson, Vidit Sharma, Stephen A. Boorjian, et al. Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis. Eur Urol 2025;88:212-4.." European urology, 2025.
PMID
41381293